Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Investing Activities (2019 - 2023)

Historic Cash from Investing Activities for Cyclerion Therapeutics (CYCN) over the last 4 years, with Q3 2023 value amounting to $10.4 million.

  • Cyclerion Therapeutics' Cash from Investing Activities changed N/A to $10.4 million in Q3 2023 from the same period last year, while for Dec 2024 it was $10.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.4 million for FY2023, which is N/A changed from last year.
  • As of Q3 2023, Cyclerion Therapeutics' Cash from Investing Activities stood at $10.4 million.
  • Cyclerion Therapeutics' Cash from Investing Activities' 5-year high stood at $10.4 million during Q3 2023, with a 5-year trough of -$4.2 million in Q2 2019.
  • Over the past 4 years, Cyclerion Therapeutics' median Cash from Investing Activities value was -$36000.0 (recorded in 2020), while the average stood at $430166.7.
  • As far as peak fluctuations go, Cyclerion Therapeutics' Cash from Investing Activities skyrocketed by 153600.0% in 2020, and later plummeted by 33333.33% in 2021.
  • Over the past 4 years, Cyclerion Therapeutics' Cash from Investing Activities (Quarter) stood at -$100000.0 in 2019, then surged by 1536.0% to $1.4 million in 2020, then plummeted by 100.49% to -$7000.0 in 2021, then soared by 148700.0% to $10.4 million in 2023.
  • Its Cash from Investing Activities stands at $10.4 million for Q3 2023, versus -$7000.0 for Q3 2021 and $2000.0 for Q2 2021.